Capital Stock and Stockholders' Deficit - Additional Information (Details) - USD ($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3 Months Ended |
12 Months Ended |
|
Feb. 24, 2026 |
Nov. 12, 2025 |
Nov. 11, 2025 |
Feb. 20, 2025 |
Feb. 19, 2025 |
Jan. 27, 2025 |
Jan. 24, 2025 |
Jan. 14, 2025 |
Jul. 05, 2024 |
Jul. 01, 2024 |
Jun. 28, 2024 |
Dec. 18, 2023 |
Aug. 01, 2023 |
Mar. 31, 2026 |
Mar. 31, 2025 |
Dec. 31, 2025 |
Mar. 06, 2026 |
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred stock, shares authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
100,000,000
|
|
100,000,000
|
|
| Preferred stock, shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
| Warrants converted into warrants exercisable |
|
|
|
|
|
|
|
|
|
|
|
|
|
9,996,437
|
|
7,336,872
|
|
| Preferred stock, par value |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.0001
|
|
$ 0.0001
|
|
| Number of shares authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
1,000,000,000
|
|
1,000,000,000
|
|
| Par value common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.0001
|
|
$ 0.0001
|
|
| Number of shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
14,994,486
|
|
12,279,181
|
|
| Number of shares issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
14,994,486
|
|
12,279,181
|
|
| Warrant liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5,096,000
|
|
$ 5,829,000
|
|
| Warrants outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
14,380
|
|
|
|
| Issuance of convertible preferred stock for the exercise of warrant (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
750,394
|
|
|
|
|
| Warrants exercisable price |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 202.5
|
|
|
|
| Other income (expense), net |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 49,000
|
$ (213,000)
|
|
|
| Changes in fair value of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
(4,324,000)
|
$ (5,669,000)
|
|
|
| Additional paid-in capital |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 173,011,000
|
|
$ 168,627,000
|
|
| ChEF Purchase Agreement | Chardan Equity Facility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares sold per unit |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
377,879
|
|
| Amount received on shares sold per unit |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,800,000
|
|
| Stock issued during period value |
|
|
|
|
|
|
|
|
|
|
|
$ 100,000,000
|
|
|
|
|
|
| Additional paid-in capital |
|
|
|
|
|
|
|
|
|
|
|
100,000
|
|
|
|
|
|
| Expense of issuance of commitment shares |
|
|
|
|
|
|
|
|
|
|
|
100,000
|
|
|
|
|
|
| Structuring fee payable |
|
|
|
|
|
|
|
|
|
|
|
$ 100,000
|
|
|
|
|
|
| Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants converted into warrants exercisable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.056818
|
| Warrants exercisable price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 202.5
|
| Sale of stock |
|
|
|
|
|
|
|
|
|
|
|
|
$ 202.5
|
|
|
|
|
| Common Stock | ChEF Purchase Agreement | Chardan Equity Facility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
379,299
|
|
|
|
|
|
| Percentage of common stock, shares, outstanding |
|
|
|
|
|
|
|
|
|
|
|
19.99%
|
|
|
|
|
|
| Commitment Shares | ChEF Purchase Agreement | Chardan Equity Facility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares sold per unit |
|
|
|
|
|
|
|
|
|
|
|
1,421
|
|
|
|
|
|
| Warrants Issued in July 2024 | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants converted into warrants exercisable |
|
|
|
|
|
|
|
|
|
|
|
|
|
753,108
|
|
753,108
|
|
| Warrants exercisable price |
|
|
|
|
|
|
$ 30
|
|
|
|
|
|
|
$ 11.42
|
|
$ 11.42
|
|
| RTW Convertible Notes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Other income (expense), net |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,100,000
|
|
|
|
| RTW Convertible Notes | Series B Convertible Preferred Stock | Exchange Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred stock, par value |
|
|
$ 0.0001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Risk-free interest rate |
|
|
3.60%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
117.50%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Public Warrant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 13,206,720
|
|
|
|
| Issuance of convertible preferred stock for the exercise of warrant (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
750,383
|
|
|
|
| Public Offering |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants converted into warrants exercisable |
|
|
|
|
|
|
|
|
|
86,440
|
576,261
|
|
|
|
|
|
|
| Sale of stock |
|
|
|
|
|
|
|
|
|
|
$ 30
|
|
|
|
|
|
|
| Number of shares sold per unit |
|
|
|
|
|
|
|
|
|
662,701
|
576,261
|
|
|
|
|
|
|
| Net proceeds from offering |
|
|
|
|
|
|
|
|
|
$ 15,200,000
|
|
|
|
|
|
|
|
| Offering cost |
|
|
|
|
|
|
|
|
|
1,000,000
|
|
|
|
|
|
|
|
| Underwriting discounts |
|
|
|
|
|
|
|
|
|
1,000,000
|
|
|
|
|
|
|
|
| Public Offering Warrants and Share Overallotment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issue-date estimated fair value |
|
|
|
|
|
|
|
|
|
13,200,000
|
|
|
|
|
|
|
|
| Net proceeds from offering |
|
|
|
|
|
|
|
|
|
17,400,000
|
|
|
|
|
|
|
|
| Offering cost |
|
|
|
|
|
|
|
|
|
800,000
|
|
|
|
|
|
|
|
| Public Offering Warrants and Share Overallotment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds from offering |
|
|
|
|
|
|
|
|
|
5,100,000
|
|
|
|
|
|
|
|
| Public Offering Warrants and Share Overallotment | Additional Paid-in Capital |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds from offering |
|
|
|
|
|
|
|
|
|
$ 5,100,000
|
|
|
|
|
|
|
|
| Private Placement with RTW | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate purchase price |
|
|
|
|
|
|
|
$ 2,500,000
|
|
|
|
|
|
|
|
|
|
| Sale of stock |
|
|
|
|
|
|
|
$ 2.97
|
|
|
|
|
|
|
|
|
|
| Number of shares sold per unit |
|
|
|
|
|
|
|
841,751
|
|
|
|
|
|
|
|
|
|
| Underwriters |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants exercisable price |
|
|
|
|
|
|
|
|
$ 30
|
|
|
|
|
|
|
|
|
| Number of shares sold per unit |
|
|
|
|
|
|
|
|
77,091
|
|
|
|
|
|
|
|
|
| Net proceeds from offering |
|
|
|
|
|
|
|
|
$ 2,200,000
|
|
|
|
|
|
|
|
|
| January 2025 Offering |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants converted into warrants exercisable |
|
|
|
|
|
|
1,240,000
|
|
|
|
|
|
|
|
|
|
|
| January 2025 Offering | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares sold per unit |
|
|
|
|
|
|
1,240,000
|
|
|
|
|
|
|
|
|
|
|
| January 2025 Private Placement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants converted into warrants exercisable |
|
|
|
|
|
|
1,240,000
|
|
|
|
|
|
|
|
|
|
|
| Sale of stock |
|
|
|
|
|
|
$ 6
|
|
|
|
|
|
|
|
|
|
|
| January 2025 Offering and January 2025 Private Placement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds from offering |
|
|
|
|
|
$ 5,800,000
|
|
|
|
|
|
|
|
|
|
|
|
| Placement agent fees |
|
|
|
|
|
600,000
|
|
|
|
|
|
|
|
|
|
|
|
| Offering cost |
|
|
|
|
|
1,000,000
|
|
|
|
|
|
|
|
|
|
|
|
| January 2025 Offering and January 2025 Private Placement | Warrants Issued in July 2024 | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants exercisable price |
|
|
|
|
|
|
$ 6
|
|
|
|
|
|
|
|
|
|
|
| February 2025 Offering |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants converted into warrants exercisable |
|
|
|
|
1,800,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| February 2025 Offering | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares sold per unit |
|
|
|
|
900,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| February 2025 Private Placement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants converted into warrants exercisable |
|
|
|
|
1,800,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sale of stock |
|
|
|
|
$ 5.23
|
|
|
|
|
|
|
|
|
|
|
|
|
| February 2025 Offering and February 2025 Private Placement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds from offering |
|
|
|
$ 3,900,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Placement agent fees |
|
|
|
400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering cost |
|
|
|
$ 400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Leavitt Private Placement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants converted into warrants exercisable |
|
|
|
|
535,372
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants exercisable price |
|
|
|
$ 30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sale of stock |
|
|
|
|
$ 5.23
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds from offering |
|
|
|
$ 1,300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Placement agent fees |
|
|
|
100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Leavitt Private Placement | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares sold per unit |
|
|
|
|
267,686
|
|
|
|
|
|
|
|
|
|
|
|
|
| January 2025 Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issue-date estimated fair value |
|
|
|
|
|
5,300,000
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds from offering |
|
|
|
|
|
5,800,000
|
|
|
|
|
|
|
|
|
|
|
|
| Offering cost |
|
|
|
|
|
800,000
|
|
|
|
|
|
|
|
|
|
|
|
| January 2025 Warrants | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds from offering |
|
|
|
|
|
1,300,000
|
|
|
|
|
|
|
|
|
|
|
|
| January 2025 Warrants | Additional Paid-in Capital |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds from offering |
|
|
|
|
|
$ 1,300,000
|
|
|
|
|
|
|
|
|
|
|
|
| February 2025 Offering Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issue-date estimated fair value |
|
|
|
5,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds from offering |
|
|
|
5,200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering cost |
|
|
|
400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| February 2025 Offering Warrants | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds from offering |
|
|
|
600,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| February 2025 Offering Warrants | Additional Paid-in Capital |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds from offering |
|
|
|
$ 600,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| January Warrant Repricing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Other income (expense), net |
|
|
|
|
|
|
$ (500,000)
|
|
|
|
|
|
|
|
|
|
|
| February Warrant Repricing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants exercisable price |
|
|
|
$ 6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Other income (expense), net |
|
|
|
$ (200,000)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| November 2025 Offering |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants converted into warrants exercisable |
|
|
2,994,012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| November 2025 Offering | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares sold per unit |
|
|
2,994,012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| November 2025 Private Placement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants converted into warrants exercisable |
|
|
2,994,012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sale of stock |
|
|
$ 1.67
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| November 2025 Offering Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issue-date estimated fair value |
|
$ 3,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds from offering |
|
5,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Placement agent fees |
|
400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| November 2025 Offering Warrants | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds from offering |
|
1,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| November 2025 Offering Warrants | Additional Paid-in Capital |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds from offering |
|
1,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| November 2025 Offering and Private Placement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds from offering |
|
4,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Placement agent fees |
|
400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering cost |
|
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Inducement Letter with Exercising Holders |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issue-date estimated fair value |
$ 5,900,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Changes in fair value of warrants |
$ 1,700,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Inducement Letter with Exercising Holders | Existing Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants exercisable price |
$ 1.15
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds from offering |
$ 2,900,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Placement agent fees |
200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering cost |
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Inducement Letter with Exercising Holders | Existing Warrants | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants converted into warrants exercisable |
2,659,565
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Inducement Letter with Exercising Holders | New Warrants | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants converted into warrants exercisable |
5,319,130
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Inducement Letter with Exercising Holders | Initial Exercise Date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants exercisable price |
$ 1.15
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Compute Health |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sale of stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 10
|
|
|
|
| Compute Health | Public Warrant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares sold per unit |
|
|
|
|
|
|
|
|
|
|
|
|
|
0.5
|
|
|
|
| Compute Health | IPO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant Exchanged |
|
|
|
|
|
|
|
|
|
|
|
|
|
0.6125
|
|
|
|
| Number of shares sold per unit |
|
|
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
| Class A Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Par value common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.0001
|
|
|
|
| Number of shares sold per unit |
|
|
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
| Class A Common Stock | Compute Health | IPO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares issuable for each outstanding warrants exercised |
|
|
|
|
|
|
|
|
|
|
|
|
|
0.056818
|
|
|
|
| Sale of stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 11.5
|
|
|
|
| Series B Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred stock redemption basis |
|
|
|
|
|
|
|
|
|
|
|
|
|
Series B Preferred StockOn November 11, 2025, the Company entered into a securities purchase and exchange agreement (the "Exchange Agreement") with certain entities managed by RTW, pursuant to which RTW has agreed to exchange all of the (i) principal amount of the RTW Convertible Notes, purchased pursuant to the terms of the Amended Note Purchase Agreement, including interest accrued on the RTW Convertible Notes; (ii) Company obligations under the Revenue Interest Financing Agreement; and (iii) Company obligations under the New RIFA, for shares of a newly issued series of Series B convertible preferred stock, par value $0.0001 per share ("Series B Preferred Stock"), of the Company (the "Exchange"). Allurion's charter authorizes the issuance of up to 100,000,000 shares of Allurion preferred stock. As of March 31, 2026, no shares of Allurion preferred stock were outstanding.
|
|
|
|
| Preferred stock, shares authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
100,000,000
|
|
|
|
| Series B Preferred Stock | Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred stock, shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|